Management of Upper Gastrointestinal Bleeding in Patients on Antiplatelet Therapy

Initial Management of UGI Bleeding on Antiplatelet Therapy

For patients on aspirin for primary prophylaxis of cardiovascular events, permanently discontinue aspirin as the bleeding risk outweighs cardiovascular benefit 1
For patients on aspirin for secondary prevention, temporarily withhold aspirin only during active serious or life-threatening bleeding 2, 3
For patients on dual antiplatelet therapy, never withhold both antiplatelet agents simultaneously due to high risk of stent thrombosis, which can occur in as little as 7 days 4, 2
In patients on DAPT with aspirin and clopidogrel, continue aspirin and temporarily withhold clopidogrel during active bleeding 4, 2
For patients on direct oral anticoagulants, interrupt therapy at presentation with UGI bleeding 1

For patients on aspirin for secondary prevention, restart aspirin as soon as hemostasis is achieved 1, 5
For patients on P2Y12 receptor antagonists, restart therapy within 5 days after endoscopic hemostasis 1, 4, 2
For patients on ticagrelor, consider earlier resumption within 2-3 days compared to clopidogrel or prasugrel 4
For patients on DOACs, consider restarting treatment at a maximum of 7 days after bleeding has stopped 1

The risk-benefit analysis of discontinuing antiplatelet therapy depends on indication for antiplatelet therapy, type of coronary stent and timing of placement, severity of bleeding, and success of endoscopic hemostasis 1, 5, 4, 2, 6
For patients with very high thrombotic risk, consult with a cardiologist before any changes to antiplatelet therapy and continue aspirin throughout the bleeding episode if possible 5, 4, 2

Initiate high-dose proton pump inhibitor therapy for all patients with UGI bleeding on antiplatelet therapy 5, 4

Discontinuation of aspirin for secondary prevention is associated with a nearly sevenfold increase in risk for death or acute cardiovascular events 5
All-cause mortality is 10 times lower in patients who resume aspirin immediately after endoscopic hemostasis compared to those who discontinue it 5

Unnecessarily prolonged discontinuation of antiplatelet therapy, especially aspirin for secondary prevention, increases thrombotic risk and mortality 5
Simultaneous discontinuation of both antiplatelet agents in patients on DAPT can lead to stent thrombosis in as little as 7 days 4, 2
Overlooking the potential drug-drug interaction between PPIs and clopidogrel, particularly in certain populations with high prevalence of CYP2C19 slow metabolizers 4
Administering platelet transfusions for patients on antiplatelet therapy with GI bleeding, which has not been shown to reduce rebleeding and may be associated with higher mortality 4

In patients with acute gastrointestinal bleeding who are taking antiplatelet agents (without thrombocytopenia), retrospective cohort studies found that platelet transfusion does not reduce re‑bleeding rates and is associated with a markedly higher mortality (adjusted odds ratio ≈ 5.6; 95 % CI 1.5–27). This evidence is derived from observational data and is considered low‑to‑moderate quality. 7
Multiple retrospective investigations have consistently failed to demonstrate any clinical benefit of platelet transfusion for gastrointestinal bleeding linked to antiplatelet therapy. The studies reported no reduction in re‑bleeding or mortality, although methodological limitations (e.g., selection bias) were noted. Evidence level: retrospective observational. [7] [8]

In the setting of hemorrhagic shock in a patient receiving dual antiplatelet therapy (aspirin + P2Y12 inhibitor), expert consensus proposes that platelet transfusion can be used to neutralize antiplatelet effects, with a target platelet count of ≥ 75 × 10⁹/L. This recommendation is based on limited observational data and expert opinion (low‑quality evidence). 7
For other severe gastrointestinal hemorrhages, platelet transfusion should be reserved only for cases where bleeding persists after failure of initial endoscopic therapy and standard symptomatic measures. This guidance stems from retrospective analyses and reflects a conditional, low‑strength recommendation. [7] [8]